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HEPATOTROPHIC PROPERTIES IN DOGS OF HUMAN FKBP, THE BINDING PROTEIN 
FOR FK506 AND RAPAMYCIW 
Cyclosporine and FK506 have been shown with two experi-
mental models to influence liver structure, function, and the 
capacity for regeneration. Both drugs augment the liver regen-
eration in rats that is the normal response to partial hepatec-
tomy (1). In addition, the increase in hepatocyte replication 
that is caused by portacaval shunt in dogs is more than doubled 
by intrahepatic infusion of these drugs via the tied-off central 
portal vein. Also, the atrophy and organelle disruption caused 
by portacaval shunt is prevented (2, 3). Immune modulation of 
lymphocytes and NK cells as an explanation for these so-called 
"hepatotrophic" effects has been ruled out by direct experimen-
tation in nude rats (4). 
The foregoing findings, as well as observations of manifold 
metabolic effects in patients treated either with FK506 or with 
cyclosporine, have led to a hypothesis that these drugs modify 
signal transduction in a variety of cells, not limited to those of 
the immune system (3, 5). Consistent with the hypothesis is 
the recent demonstration that FK506 and cyclosporine inhibit 
signaling processes in the mast cell at concentrations similar 
to those used to block signaling pathways in T cells (6; also 
Schreiber SL, et al., unpublished observations). Central to the 
signal transduction hypothesis was the discovery that the cy-
tosolic receptors for FK506 and rapamycin (FK506-binding 
protein, FKBP)* and cyclosporine (cyclophilin) are distinct 
proteins that exhibit peptidyl-prolyl cis trans isomerase (rota-
mase) activity (7, 8). Rotamases have been shown to facilitate 
protein folding (9, 10) and to catalyze the interconversion of 
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* Abbreviation: FKBP, FK506-binding protein. 
rotamers of peptidyl-prolyl bonds in vitro (11, 12). However, 
the inhibition of this enzymatic activity is not related to the 
action of these drugs in the T cell (13) or the mast cell 
(Schreiber SL, Hohman RJ, et al., unpublished observations). 
Instead, these proteins are envisioned as members of a class of 
small molecular weight cytoplasmic proteins (collectively called 
immunophilins) that modulate a wide variety of calcium-
dependent signal transduction pathways by forming complexes 
with immunosuppressive drugs (13, 14). The potential impor-
tance and pleiotropism of the immunophilin network is empha-
sized by the ubiquitous distribution of cyclophilin as detected 
by immunocytochemical techniques in the cytoplasm of vir-
tually all cells in the body, and in the nuclei of some (15, 16). 
How the immunophilins are activated by immunosuppressive 
agents is not known, nor is it known if modulation of the 
immunophilin's activity requires binding of an exogenous 
(drug) or endogenous ligand. With the cloning and overexpres-
sion of FKBP in bacteria (17), it became possible to test the 
intrinsic activity of FKBP, free of drug. Briefly, with the use 
of the expression cassette polymerase chain reaction (18), the 
proper sequences were added to the FKBP cDNA that allow 
for its overexpression in E. coli. Following a simple purification 
protocol (17), recombinant human FKBP was demonstrated to 
be pure by SDS-PAGE analysis. 
The recombinant FKBP was dissolved in normal saline mod-
ified by the addition of 5 mM ammonium acetate and 5 mgjL 
bovine serum albumin (to prevent adhesion to the plastic 
tubing). After performing completely diverting portacaval 
shunt, an infusion catheter was inserted into the tied-off left 
portal vein for pump-driven constant infusion of the FKBP 
over the next 4 days. At the end of 4 days, the animals were 
injected with 0.2 mci/kg intravenous 3H-thymidine (New Eng-
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TABLE 1. Effect of cloned FKBP infusion in left portal branch for 4 days after canine ECK fistula 
Hepatocyte (size of units) Labelled nuclei (per 1000 hepatocytes) 
1 
2 
3 
4 
5 
6 
7 
8 
Animal No. Drug dose (jkgjday) 
Insulin 
FKBP 
FKBP 
FKBP 
FKBP 
0.4 units 
200 ng 
500 ng 
500 ng 
1000 ng 
Left 
0.0812 
0.0999 
0.0899 
0.1497 
0.1149 
0.1174 
0.1181 
0.1298 
Right Left Right 
0.0764 3.9 4.0 
0.1007 4.1 4.0 
0.0979 4.0 4.1 
0.0924 10.2 4.2 
0.1003 5.0 4.0 
0.1011 5.8 3.8 
0.1032 6.7 4.2 
0.1053 8.2 4.1 
Controls (n = 4) 0.1005±0.007 0.0980±0.020 3.98±0.06 3.91±0.06 
land Nuclear, Boston) and killed 2 hr later. Specimens were 
obtained for comparison of the hepatocytes in the left (infused) 
and right (not infused) liver lobes using previously described 
morphometric and autoradiographic techniques (3, 19). Auto-
radiography was carried out with Kodak NTB2 liquid emulsion 
with an exposure time of at least 30 days. The number of 
replicating hepatocytes as an index of hepatocyte regeneration 
was determined by counting the number of 3H-thymidine-
labeled nuclei per 1000 hepatocytes. The size of individual 
hepatocytes (index of hypertrophy or atrophy) was determined 
by tracing out at least 500 midzonal liver cells projected on 
standard-thickness paper, cutting out the individual silhou-
ettes, and weighing each. This method has been shown to be 
accurate for determining hepatocyte cell size and has been 
validated by planimetry and by studies of unicellular organisms, 
the size of which has been determined directly. An insulin 
infusion, which we use to verify the integrity of the test system 
(2, 19), prevented the usual hepatocyte atrophy and increased 
the hepatocyte proliferation in the directly infused lobes only 
(Table 1). 
Because it has been assumed that immunophilins are acti-
vated by binding with a drug or other ligands, it was suspected 
when these experiments were planned that the cloned FKBP 
would be inert. Instead, a substantial dose-related hepato-
trophic response was caused (Table 1), with partial prevention 
of the hepatocyte atrophy and augmentation of hepatocyte 
proliferation in the directly infused lobes only. This is the first 
demonstration of a physiologic action of an unbound immu-
nophilin, and one with important implications. One possibility 
for resolving the discrepancy that a cytosolic protein has a 
physiologic activity outside of the cell is that there may be a 
secretory variant of the FKBP family that has hepatotrophic 
effects. Thus, one ~ould argue that the extracellular concentra-
tion of this putative hormone has been increased by infusing a 
closely related protein into the liver. An alternative possibility 
is that the recombinant FKBP bound with a natural circulating 
ligand, and that the complex activated regulatory growth fac-
tors, possibly including cytokines. 
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